Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Jules H. Blank MD

Adjunct Assistant Professor

Institution: Medical College of Wisconsin
Department: Medical School Regional Campuses
Division: Green Bay
Program: Green Bay


Publications (3)

  • A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. (Fenske TS, Shah NM, Kim KM, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS) Cancer 2015 Oct 01;121(19):3465-71 PMID: 26079295 SCOPUS ID: 2-s2.0-84941940489 06/17/2015       37 Citations
  • Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. (Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM) Invest New Drugs 2014 Feb;32(1):195-9 PMID: 23728919 PMCID: PMC4310688 SCOPUS ID: 2-s2.0-84899061436 06/04/2013       36 Citations
  • Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. (Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W, Rezazedeh H, Werndli JE, Bailey HH, Kahl BS) Leuk Lymphoma 2011 Sep;52(9):1675-80 PMID: 21864042 PMCID: PMC3489168 SCOPUS ID: 2-s2.0-80052062419 08/26/2011       37 Citations
  • Last update: 11/13/2019